CD21 antibody | CA2.1D6

Mouse anti Canine CD21:Alexa Fluor® 647

Product Type
Monoclonal Antibody

Product Code Applications Pack Size List Price Your Price Qty
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
F 100 Tests/1ml loader
List Price Your Price
Search for Batch Specific Datasheets

Mouse anti Canine CD21 antibody, clone CA2.1D6 recognizes canine CD21, also known as Complement receptor type 2. CD21 is a cell surface antigen expressed by canine B lymphocytes.

The antigen recognized may be the canine homologue of human CD21, but this has not been fully confirmed.

Mouse anti Canine CD21 antibody , clone CA2.1D6 also recognizes the CD21 antigen in Felids. Expression in cats is analogous to that seen in dogs with strong expression on lymphocytes, in a manner mutually exclusive with expression of CD4 or CD8. Mouse anti Canine CD21 antibody, clone CA2.1D6 immunoprecipitates a ~145 kDa protein from feline lymphocytes, similar to the protein immunoprecipitated by the antibody from canine lymphocytes (Dean et al. 1996).

Target Species
Species Cross-Reactivity
Target SpeciesCross Reactivity
N.B. Antibody reactivity and working conditions may vary between species.
Product Form
Purified IgG conjugated to Alexa Fluor® 647 - liquid
Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
Approx. Protein Concentrations
IgG concentration 0.05mg/ml
Max Ex/Em
Fluorophore Excitation Max (nm) Emission Max (nm)
Alexa Fluor®647 650 665
For research purposes only
12 months from date of despatch
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat 1/10
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.

Description Product Code Applications Pack Size List Price Your Price Quantity
Mouse IgG1 Negative Control:Alexa Fluor® 647 MCA928A647 F 100 Tests/1ml loader
List Price Your Price
Description Mouse IgG1 Negative Control:Alexa Fluor® 647

References for CD21 antibody

  1. Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
    Tissue Antigens. 43 (3): 137-54.
  2. Brodersen, R. et al. (1998) Analysis of the immunological cross reactivities of 213 well characterized monoclonal antibodies with specificities against various leucocyte surface antigens of human and 11 animal species.
    Vet Immunol Immunopathol. 64 (1): 1-13.
  3. Dean, G.A. et al. (1996) Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node.
    J Virol. 70 (8): 5165-9.
  4. Faldyna, M. et al. (2004) Lymphocyte subsets in synovial fluid from clinically healthy joints of dogs.
    Acta Vet. Brno 73: 73-8.
  5. Bund, D. et al. (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies.
    Cell Immunol. 263: 88-98.
  6. Huang, Y.C. et al. (2008) CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells.
    J Leukoc Biol. 84: 1501-10.
  7. Mortarino, M. et al. (2009) ZAP-70 and Syk expression in canine lymphoid cells and preliminary results on leukaemia cases.
    Vet Immunol Immunopathol. 128: 395-401.
  8. Reggeti, F. et al. (2008) CD134 and CXCR4 expression corresponds to feline immunodeficiency virus infection of lymphocytes, macrophages and dendritic cells.
    J Gen Virol. 89: 277-87.
  9. View The Latest Product References
  10. Wang, Y.S. et al. (2007) Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation.
    Can J Vet Res. 71: 165-74.
  11. Lankford, S. et al. (2008) Cloning of feline FOXP3 and detection of expression in CD4+CD25+ regulatory T cells.
    Vet Immunol Immunopathol. 122: 159-66.
  12. Araujo, M.S. et al. (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis.
    Vet Immunol Immunopathol. 141: 64-75.
  13. Estrela-Lima, A. et al. (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates.
    BMC Cancer. 10: 256.
  14. Horn, P.A. et al. (2004) Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol.
    Blood. 103: 3710-6.
  15. Hsiao, Y.W. et al. (2004) Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity.
    J Immunol. 172: 1508-14.
  16. Jubala, C.M. et al. (2005) CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma.
    Vet Pathol. 42: 468-76.
  17. Gaurnier-Hausser, A. et al. (2011) NEMO-Binding Domain Peptide Inhibits Constitutive NF-{kappa}B Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma.
    Clin Cancer Res. 17: 4661-71.
  18. Maiolini, A. et al. (2012) Toll-like receptors 4 and 9 are responsible for the maintenance of the inflammatory reaction in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis.
    J Neuroinflammation. 9: 226.
  19. Cave, N.J. et al. (2012) Systemic effects of periodontal disease in cats.
    Vet Q. 32: 131-44.
  20. Yuasa, K. et al. (2007) Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
    Gene Ther. 14: 1249-60.
  21. Aresu, L. et al. (2014) VEGF and MMP-9: biomarkers for canine lymphoma.
    Vet Comp Oncol. 12: 29-36.
  22. Heinrich, F. et al. (2015) Immunophenotyping of immune cell populations in the raccoon (Procyon lotor).
    Vet Immunol Immunopathol. 168 (3-4): 140-6.
  23. Gelain, M.E. et al. (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood.
    Vet Immunol Immunopathol. 159 (1-2): 91-6.
  24. Michael, H.T. et al. (2013) Isolation and characterization of canine natural killer cells.
    Vet Immunol Immunopathol. 155 (3): 211-7.
  25. Mitchell, L. et al. (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma.
    Vet Immunol Immunopathol. 145 (3-4): 597-603.
  26. Bonnefont-Rebeix, C. et al. (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology.
    Immunobiology. 221 (1): 12-22.
  27. Izci C et al. (2015) Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine.
    Biotech Histochem. 90 (3): 223-30.
  28. Ledbetter, E.C. et al. (2016) Clinical and immunological assessment of therapeutic immunization with a subunit vaccine for recurrent ocular canine herpesvirus-1 infection in dogs.
    Vet Microbiol. 197: 102-10.
  29. Lin, S-C. et al. (2014) Immune Characterization of Peripheral Blood Mononuclear cells of the Dogs Restored from Innoculation of Canine Transmissible Venereal Tumor Cells.
    Tai Vet J. 40 (04): 181-90.
  30. Herry, V. et al. (2017) Local immunization impacts the response of dairy cows to Escherichia coli mastitis.
    Sci Rep. 7 (1): 3441.
  31. Gibbons, N. et al. (2017) Phenotypic heterogeneity of peripheral monocytes in healthy dogs.
    Vet Immunol Immunopathol. 190: 26-30.
  32. Martini, V. et al. (2018) Flow cytometry for feline lymphoma: a retrospective study regarding pre-analytical factors possibly affecting the quality of samples.
    J Feline Med Surg. 20 (6): 494-501.
  33. Declue, A.E. et al. (2018) Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy.
    BMC Vet Res. 14 (1): 119.
  34. DaSilva, A.V.A. et al. (2018) Morphophysiological changes in the splenic extracellular matrix of Leishmania infantum-naturally infected dogs is associated with alterations in lymphoid niches and the CD4+ T cell frequency in spleens.
    PLoS Negl Trop Dis. 12 (4): e0006445.
  35. Schmidli, M.R. et al. (2018) Inflammatory pattern of the infrapatellar fat pad in dogs with canine cruciate ligament disease.
    BMC Vet Res. 14 (1): 161.
  36. Miranda, L.H.M de M. et al. (2018) Co-infection with feline retrovirus is related to changes in immunological parameters of cats with sporotrichosis.
    PLoS One. 13 (11): e0207644.
  37. Maeta, N. et al. (2019) Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats.
    Open Vet J. 9 (2): 147-50.
  38. Sato, M. et al. (2018) Prognostic significance of hypermethylation of death-associated protein kinase (DAPK) gene CpG island in dogs with high-grade B-cell lymphoma.
    Vet Comp Oncol. 16 (3): 409-15.
  39. Aricò, A. et al. (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.
    BMC Vet Res. 9: 94.
  40. Aguiar-Soares, R.D.O. et al. (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis.
    Vaccines (Basel). 8 (4)Nov 17 [Epub ahead of print].
  41. Jimbo, S. et al. (2019) Natural and inducible regulatory B cells are widely distributed in ovine lymphoid tissues.
    Vet Immunol Immunopathol. 211: 44-8.
  42. Martini, V. et al. (2019) Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy.
    Res Vet Sci. 125: 130-5.
  43. Wolf-Ringwall, A. et al. (2020) Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol.
    Vet Comp Oncol. 18 (3): 342-52.
  44. Lucassen, A. et al. (2021) A Saccharomyces cerevisiae Fermentation Product (Olimond BB) Alters the Early Response after Influenza Vaccination in Racehorses.
    Animals (Basel). 11(9):2726.
  45. Lee, J. et al. (2021) Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor.
    Biomed Res Int. 2021: 6690704.
  46. Shin, N. et al. (2018) INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies.
    J Pharmacol Exp Ther. 364 (1): 120-30.
  47. Grudzien, M. et al. (2021) A newly established canine NK-type cell line and its cytotoxic properties.
    Vet Comp Oncol. 19 (3): 567-77.
  48. Yang, Y. et al. (2021) Canine Multicentric Large B Cell Lymphoma with Increased Mott Cells Diagnosed by Flow Cytometry
    Journal of Veterinary Clinics. 38 (1): 36-40.
  49. Lee, S.H. et al. (2021) Safety and immunological effects of recombinant canine IL-15 in dogs.
    Cytokine. 148: 155599.
  50. Knebel, A. et al. (2021) Measurement of canine Th17 cells by flow cytometry.
    Vet Immunol Immunopathol. 243: 110366.
  51. Riccardo, F. et al. (2022) Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
    J Immunother Cancer. 10(5):e004007. [Epub ahead of print].

Flow Cytometry

Immunohistology - Frozen

View more products with CD21 specificity

Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"

View all Anti-Dog Products